ELVN has been in the news 900% more than usual
Jan 08, 2026, 5:33 PM
17.50%
What does ELVN do
Enliven Therapeutics, a clinical stage precision oncology company based in Boulder, Colorado, went public on March 12, 2020. It is developing ELVN-001 for chronic myeloid leukemia and ELVN-002 for HER2 mutations.
ELVN has been in the news recently: Scott Garland has joined the Board of Enliven Therapeutics as the company gears up for a Phase 3 trial of its drug ELVN-001, targeting chronic myeloid leukemia in 2026. The company's recent developments come amidst a mixed performance in U.S. stocks, with notable gains reported in profits due to strong sales and cost management.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.